[go: up one dir, main page]

WO2002032375A8 - Utilisations d'anticorps monoclonal 8h9 - Google Patents

Utilisations d'anticorps monoclonal 8h9

Info

Publication number
WO2002032375A8
WO2002032375A8 PCT/US2001/032565 US0132565W WO0232375A8 WO 2002032375 A8 WO2002032375 A8 WO 2002032375A8 US 0132565 W US0132565 W US 0132565W WO 0232375 A8 WO0232375 A8 WO 0232375A8
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
provides
derivative
binding
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/032565
Other languages
English (en)
Other versions
WO2002032375A2 (fr
WO2002032375A3 (fr
WO2002032375A9 (fr
Inventor
Nai-Kong V Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01983999A priority Critical patent/EP1399187A4/fr
Priority to CA002423843A priority patent/CA2423843A1/fr
Priority to AU2002215383A priority patent/AU2002215383A1/en
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to US10/097,558 priority patent/US7737258B2/en
Publication of WO2002032375A2 publication Critical patent/WO2002032375A2/fr
Publication of WO2002032375A3 publication Critical patent/WO2002032375A3/fr
Publication of WO2002032375A8 publication Critical patent/WO2002032375A8/fr
Priority to AU2002362846A priority patent/AU2002362846A1/en
Priority to CA2463017A priority patent/CA2463017C/fr
Priority to EP02801782A priority patent/EP1441765A4/fr
Priority to PCT/US2002/033331 priority patent/WO2003033670A2/fr
Priority to US10/273,762 priority patent/US7666424B2/en
Publication of WO2002032375A9 publication Critical patent/WO2002032375A9/fr
Priority to US10/505,658 priority patent/US7740845B2/en
Anticipated expiration legal-status Critical
Priority to US12/709,848 priority patent/US8148154B2/en
Priority to US12/721,798 priority patent/US8414892B2/en
Priority to US12/797,081 priority patent/US8501471B2/en
Priority to US13/858,234 priority patent/US9062110B2/en
Priority to US13/958,902 priority patent/US20140161814A1/en
Priority to US15/365,803 priority patent/US9938351B2/en
Priority to US15/899,801 priority patent/US20180208673A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne une composition contenant une dose efficace d'anticorps monoclonal 8H9 ou d'un dérivé de celui-ci et un excipient approprié. Cette invention concerne une composition pharmaceutique contenant une dose efficace d'un anticorps monoclonal 8H9 ou d'un dérivé de celui-ci et un excipient pharmaceutiquement acceptable. Cette invention concerne également un anticorps autre que l'anticorps monoclonal 8H9 contenant les régions déterminantes complémentaires de l'anticorps monoclonal 8H9 ou d'un dérivé de celui-ci, capables de se fixer au même antigène que l'anticorps monoclonal 8H9. Cette invention concerne également une substance capable d'inhiber par compétition la fixation de l'anticorps monoclonal 8H9. De plus, cette invention concerne un scFv isolé d'anticorps monoclonal 8H9 ou d'un dérivé de celui-ci. L'invention a également trait à l'antigène 8H9. En outre, l'invention a trait à une méthode d'inhibition de la croissance de cellules tumorales consistant à mettre lesdites cellules tumorales en contact avec une dose appropriée d'un anticorps monoclonal 8H9 ou d'un dérivé de celui-ci.
PCT/US2001/032565 2000-10-18 2001-10-18 Utilisations d'anticorps monoclonal 8h9 Ceased WO2002032375A2 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP01983999A EP1399187A4 (fr) 2000-10-18 2001-10-18 Utilisations d'anticorps monoclonal 8h9
CA002423843A CA2423843A1 (fr) 2000-10-18 2001-10-18 Utilisations d'anticorps monoclonal 8h9
AU2002215383A AU2002215383A1 (en) 2000-10-18 2001-10-18 Uses of monoclonal antibody 8h9
US10/097,558 US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
PCT/US2002/033331 WO2003033670A2 (fr) 2001-10-17 2002-10-17 Procede de preparation d'anticorps monocatenaires
AU2002362846A AU2002362846A1 (en) 2001-10-17 2002-10-17 Method for preparation of single chain antibodies
US10/273,762 US7666424B2 (en) 2001-10-17 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
CA2463017A CA2463017C (fr) 2001-10-17 2002-10-17 Procede de preparation d'anticorps monocatenaires
EP02801782A EP1441765A4 (fr) 2001-10-17 2002-10-17 Procede de preparation d'anticorps monocatenaires
US10/505,658 US7740845B2 (en) 2000-10-18 2003-03-06 Uses of monoclonal antibody 8H9
US12/709,848 US8148154B2 (en) 2001-10-17 2010-02-22 Method for preparation of single chain antibodies
US12/721,798 US8414892B2 (en) 2000-10-18 2010-03-11 Uses of monoclonal antibody 8H9
US12/797,081 US8501471B2 (en) 2000-10-18 2010-06-09 Uses of monoclonal antibody 8H9
US13/858,234 US9062110B2 (en) 2000-10-18 2013-04-08 Uses of monoclonial antibody 8H9
US13/958,902 US20140161814A1 (en) 2000-10-18 2013-08-05 Uses of monoclonal antibody 8h9
US15/365,803 US9938351B2 (en) 2000-10-18 2016-11-30 Uses of monoclonal antibody 8H9
US15/899,801 US20180208673A1 (en) 2000-10-18 2018-02-20 Uses of monoclonal antibody 8h9

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24134400P 2000-10-18 2000-10-18
US60/241,344 2000-10-18
US33039601P 2001-10-17 2001-10-17
US60/330,396 2001-10-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/982,645 Continuation-In-Part US20020102264A1 (en) 2000-10-18 2001-10-18 Uses of monoclonal antibody 8H9

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/097,558 Continuation-In-Part US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
US10/273,762 Continuation-In-Part US7666424B2 (en) 2000-10-18 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies

Publications (4)

Publication Number Publication Date
WO2002032375A2 WO2002032375A2 (fr) 2002-04-25
WO2002032375A3 WO2002032375A3 (fr) 2002-06-20
WO2002032375A8 true WO2002032375A8 (fr) 2002-09-12
WO2002032375A9 WO2002032375A9 (fr) 2003-01-03

Family

ID=26934217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032565 Ceased WO2002032375A2 (fr) 2000-10-18 2001-10-18 Utilisations d'anticorps monoclonal 8h9

Country Status (3)

Country Link
EP (1) EP1399187A4 (fr)
CA (1) CA2423843A1 (fr)
WO (1) WO2002032375A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US7737258B2 (en) * 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
EP1511772B1 (fr) * 2002-05-28 2011-11-23 Omrix Biopharmaceuticals Inc. Methode pour obtenir des anticorps anti-idiotype
EP1565489B1 (fr) 2002-06-19 2010-11-17 Raven Biotechnologies, Inc. Anticorps spécifiques pour et qui internalisent la cible de surface cellulaire RAAG10
AU2003298794A1 (en) * 2002-12-02 2004-06-23 Us Gov Health & Human Serv Recombinant immunotoxin and use in treating tumors
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
JP5130044B2 (ja) 2004-08-03 2013-01-30 イナート・ファルマ ４ｉｇ−ｂ７−ｈ３およびその対応するｎｋ細胞受容体を標的化する治療および診断方法ならびに組成物
ES2666152T3 (es) 2009-08-13 2018-05-03 The Johns Hopkins University Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
CA2791658C (fr) 2010-03-04 2019-10-01 Macrogenics, Inc. Anticorps reagissant avec b7-h3, fragments immunologiquement actifs associes et utilisations associees
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2015123241A1 (fr) 2014-02-14 2015-08-20 Chi Andrew S Procédés améliorés pour le traitement de cancers liés à la vascularisation
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
WO2016106004A1 (fr) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Nouveaux composés de liaison anti-b7h3 et leurs utilisations
JP7320944B2 (ja) 2015-10-08 2023-08-04 マクロジェニクス，インコーポレーテッド Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
AU2017249435B2 (en) 2016-04-15 2024-05-02 Macrogenics, Inc. Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
EP4022313A1 (fr) 2019-08-30 2022-07-06 Y-Mabs Therapeutics, Inc. Évaluation immunohistochimique de l'expression de b7-h3
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
EP4172323A1 (fr) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
WO2022167052A1 (fr) 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Utilisation d'acide ascorbique comme agent stabilisant pour des anticorps anti-b7-h3
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023278641A1 (fr) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7337400A (en) * 1999-09-03 2001-04-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
US6891030B2 (en) * 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule

Also Published As

Publication number Publication date
WO2002032375A2 (fr) 2002-04-25
WO2002032375A3 (fr) 2002-06-20
EP1399187A4 (fr) 2005-09-21
EP1399187A2 (fr) 2004-03-24
CA2423843A1 (fr) 2002-04-25
WO2002032375A9 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
WO2002032375A3 (fr) Utilisations d'anticorps monoclonal 8h9
WO2003075846A3 (fr) Utilisations d'anticorps 8h9 monoclonaux
WO2002030986A3 (fr) ANTICORPS HUMANISES ANTI-LT-β-R
WO2002022851A3 (fr) Nouveau marqueur associe aux tumeurs
WO2002030985A3 (fr) Inhibition de l'activation du complement c5 pour le traitement et la prevention du rejet differe d'une xenogreffe ou d'un rejet vasculaire aigu
WO2001014424A3 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP2336187B8 (fr) Compositions et méthodes d'anticorps monoclonaux et polyclonaux spécifiques aux sous-populations de lymphocytes T
DE69939820D1 (de) Internalisierende erbb2 antikörper
EP1308455A3 (fr) Composition d'anticorps anti-HER2
WO2002016401A3 (fr) Anticorps monoclonal ds6 et ses procedes d'utilisation
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
AU6618100A (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
AU2002220843A1 (en) Humanised antibodies and uses thereof
EP2186884A3 (fr) Anticorps monoclonaux contre des antigènes du noyau de CHV
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
CA2348026A1 (fr) Anticorps anti-semp1, methodes de production et utilisations connexes
WO2002074251A3 (fr) Traitement par anticorps monoclonal du cancer du pancreas
AU7960600A (en) Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU5441000A (en) Human monoclonal antibody
WO2002034290A3 (fr) Anticorps et autres ligands dirige contre le recepteur de kir2dl4 pour la production de l'interferon gamma
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
WO2000001729A3 (fr) Peptides synthetiques et compositions pharmaceutiques les contenant, destines au diagnostic et au traitement du syndrome anti-phospholipides
AU2003210054A1 (en) Anti-rank monoclonal antibodies and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 6-11, DESCRIPTION, REPLACED BY NEW PAGES 6-11; PAGES 1/32-32/32, DRAWINGS, REPLACED BY NEW PAGES 1/32-32/32; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2423843

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2001983999

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001983999

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001983999

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP